论文部分内容阅读
目的观察孟鲁司特联合丙酸氟替卡松防治儿童哮喘的临床疗效。方法 80例哮喘患儿,随机分为观察组40例和对照组40例。对照组在常规治疗基础上,给予丙酸氟替卡松吸入气雾剂,200~800μg/d,根据病情程度选择不同剂量,连续服用30 d;观察组在对照组的基础上口服孟鲁司特,4~5 mg/次,1次/d,睡前服用,连续服用30 d。比较2组治疗后2、4周哮喘缓解例数;临床症状缓解时间、肺部体征消失时间;采用呼气峰流速(PEF)仪检测PEF。所有患儿随访6个月,统计随访期间复发情况。采用SPSS17.0统计软件,计数资料采用χ2分析,计量资料采用t检验。结果观察组治疗2、4周哮喘缓解例数(15、31例)均高于对照组(7、20例);临床症状缓解时间(2.92±0.62)d、肺部体征消失时间(4.67±0.68)d,均短于对照组(4.69±0.73)d、(5.98±0.56)d,差异有统计学意义(P<0.05或P<0.01);2组治疗后2周、4周PEF均较治疗前升高,观察组较对照组升高更明显,差异有统计学意义(P均<0.05);观察组随访6个月的复发率(2.5%)低于对照组(22.5%)(P<0.01)。结论孟鲁司特联合丙酸氟替卡松防治儿童哮喘的临床疗效确切。
Objective To observe the clinical efficacy of montelukast combined with fluticasone propionate in the prevention and treatment of childhood asthma. Methods Eighty children with asthma were randomly divided into observation group (40 cases) and control group (40 cases). The control group was given fluticasone propionate inhalation aerosol at the dose of 200-800μg / d on the basis of routine treatment for 30 days. The observation group was given montelukast on the basis of the control group, 4 ~ 5 mg / time, 1 time / d, taking at bedtime, taking 30 consecutive days. The number of asthma relief cases at 2, 4 weeks after treatment were compared; the clinical symptom relief time and the disappearance time of lung signs were compared; PEF was measured by the peak expiratory flow rate (PEF). All children were followed up for 6 months, statistics of recurrence during follow-up. Using SPSS17.0 statistical software, count data using χ2 analysis, measurement data using t test. Results The number of asthma exacerbation in the observation group was higher than that in the control group (15, 31 cases) in 2 and 4 weeks (7 and 20 cases, respectively). The clinical symptoms relief time was 2.92 ± 0.62 d and the time of lung signs disappearing was 4.67 ± 0.68 ) d were shorter than that in the control group (4.69 ± 0.73) d and (5.98 ± 0.56) d, respectively, with significant difference (P <0.05 or P <0.01) (P <0.05). The recurrence rate in the observation group at 6 months (2.5%) was lower than that in the control group (22.5%) (P < 0.01). Conclusion Montelukast combined with fluticasone propionate in the prevention and treatment of childhood asthma clinical curative effect.